Enochian Biosciences (OTCMKTS:ENOB) Trading Down 0.2%

Enochian Biosciences Inc (OTCMKTS:ENOB) dropped 0.2% during trading on Tuesday . The company traded as low as $4.65 and last traded at $4.80, approximately 10,853 shares traded hands during trading. A decline of 78% from the average daily volume of 49,080 shares. The stock had previously closed at $4.81.

The firm has a 50-day moving average price of $4.65 and a 200-day moving average price of $5.75.

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Enochian Biosciences by 316.8% during the second quarter. BlackRock Inc. now owns 221,718 shares of the company’s stock worth $998,000 after acquiring an additional 168,520 shares during the last quarter. Susquehanna International Group LLP purchased a new stake in shares of Enochian Biosciences during the 2nd quarter worth $133,000. Vanguard Group Inc. boosted its position in shares of Enochian Biosciences by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 535,607 shares of the company’s stock worth $2,411,000 after purchasing an additional 27,039 shares in the last quarter. United Capital Financial Advisers LLC purchased a new stake in shares of Enochian Biosciences during the 2nd quarter worth $105,000. Finally, Wells Fargo & Company MN acquired a new position in shares of Enochian Biosciences during the 2nd quarter worth $72,000.

About Enochian Biosciences (OTCMKTS:ENOB)

Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.

Further Reading: Why is a lock-up period needed for an IPO?

Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.